Survey of Ophthalmology
Volume 44 , Pages S155-S162 , January 2000

The Efficacy and Safety of Brinzolamide 1% Ophthalmic Suspension (Azopt®) as a Primary Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

References 

  1. Camras C, Brinzolamide Primary Therapy Study Group . A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1.0% compared to TID-doses dorzolamide 2.0% and BID-dosed timolol 0.5% (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl):S560
  2. Donohue EK, Wilensky JT. Trusopt, a topical carbonic anhydrase inhibitor. J Glaucoma. 1996;5:68–74
  3. Epstein DL, Grant M. Carbonic anhydrase inhibitor side effects. Arch Ophthalmol. 1977;95:1378–1382
  4. Lichter PR, Newman LP, Wheeler NC, Beall OV. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol. 1978;85:495–502
  5. March W, Silver L, Brinzolamide Long-Term Therapy Study Group . The long-term safety and efficacy of brinzolamide (Azopt®), a new topical carbonic anhydrase inhibitor, in patients with open angle glaucoma and ocular hypertension (abstract). Invest Ophthalmol Vis Sci. 1998;39(suppl 4):S199
  6. Shin DH, Brinzolamide Adjunctive Study Group . A triple-masked, placebo-controlled, adjunctive study of the efficacy and safety of TID-dosed brinzolamide 1.0% compared to TID-dosed placebo when used adjunctively to timolol 0.5% (abstract). Invest Ophthalmol Vis Sci. 1997;38(Suppl):S559
  7. Shin D, Brinzolamide Adjunctive Therapy Study Group . Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt®) in patients with primary open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44(suppl 2):S163–S168
  8. Silver L, Brinzolamide Primary Therapy Study Group: Clinical efficacy and safety of brinzolamide (Azopt®), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol (in press)
  9. Silver L, Brinzolamide Dose-Response Study Group . Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt®). Surv Ophthalmol. 2000;44(suppl 2):S147–S153
  10. Silver L, Brinzolamide Comfort Study Group . The ocular comfort of brinzolamide 1.0% ophthalmic suspension compared to dorzolamide 2.0% ophthalmic solution (results from two multicenter comfort studies). Surv Ophthalmol. 2000;44(suppl 2):S141–S145
  11. Stewart R, Brinzolamide Comfort Study Group . The ocular comfort of a TID-d osed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl):S559
  12. Strahlman E, Tipping R, Vogel R, Dorzolamide Dose-Response Study Group . A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol. 1996;122:183–194

☆ This study was funded by Alcon Research, Ltd.

☆☆ Dr. Sall has no commercial or proprietary interest in the products and concepts discussed in this article.

PII: S0039-6257(99)00107-1

Survey of Ophthalmology
Volume 44 , Pages S155-S162 , January 2000

Article Tools